Research Topics
| Tony P GeorgeSummaryAffiliation: Centre for Addiction and Mental Health Country: Canada Publications
| Collaborators
|
Detail Information
Publications
A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophreniaTony P George
Centre for Addiction and Mental Health, Faculty of Medicine, University of Toronto, Ontario, Canada
Biol Psychiatry 63:1092-6. 2008..We determined whether the combination of sustained-release (SR) bupropion (BUP) with the transdermal nicotine patch (TNP) was well-tolerated and superior to placebo (PLO)+TNP for smoking cessation in schizophrenia...
Prepulse inhibition deficits in schizophrenia are modified by smoking statusAndrea A Woznica
Department of Psychiatry, University of Toronto, Faculty of Medicine, 250 College Street, Toronto, Ontario, Canada
Schizophr Res 112:86-90. 2009..However, the relationship between PPI deficits and smoking status is unclear. We examined whether smoking status modifies PPI deficits in schizophrenia...- Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking statusVictoria C Wing
Centre for Addiction and Mental Health CAMH, Schizophrenia Program Division of Addiction Psychiatry, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Psychiatry Res 188:320-6. 2011..Our findings suggest that smoking status and history differentially alters neuropsychological outcomes in schizophrenia compared to non-psychiatric controls, and that never-smokers may present with more severe neurocognitive impairments... - Effects of cigarette smoking status on delay discounting in schizophrenia and healthy controlsVictoria C Wing
Department of Psychiatry, University of Toronto, Toronto, Canada
Addict Behav 37:67-72. 2012..This study examined the relationship between cigarette smoking and delay discounting in schizophrenia and control participants... - Repetitive transcranial magnetic stimulation and drug addictionMera S Barr
Schizophrenia Program, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Int Rev Psychiatry 23:454-66. 2011..Although work in this area is limited, this review indicates that rTMS is a promising modality for treating drug addiction... - A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophreniaVictoria C Wing
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Ann N Y Acad Sci 1248:89-106. 2012..In addition, suggestions for future lines of research to better understand reasons for the comorbidity of nicotine addiction in schizophrenia are discussed... - Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smokingIngrid Bacher
Vivian M Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, 250 College St, Toronto, ON, Canada
Arch Gen Psychiatry 68:817-26. 2011..Dysphoria during cigarette withdrawal predicts relapse. It is unknown whether MAO-A binding increases during early cigarette withdrawal... - Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking statusRachel A Rabin
Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Schizophr Res 114:91-7. 2009..However, little is known about how smoking status modulates the relationships between neurocognitive measures in schizophrenia and healthy control subjects... - A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilitiesTaryn G Moss
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Am J Addict 19:293-311. 2010..Finally, questions for further research in this field are delineated. This Tobacco Reconceptualization in Psychiatry is long overdue, given the clear and compelling benefits of tobacco-free environments in psychiatric institutions... - The effects of cannabis use on neurocognition in schizophrenia: a meta-analysisRachel A Rabin
The Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada
Schizophr Res 128:111-6. 2011..Explanations for these findings are discussed and suggestions for future research in this area are recommended... - Individualized smoking cessation treatment in an outpatient setting: Predictors of outcome in a sample with psychiatric and addictions co-morbidityPeter Selby
Addictions Program and Nicotine Dependence Clinic, Centre for Addiction and Mental Health, Toronto, ON, Canada M5S 2S1
Addict Behav 35:811-7. 2010..However, few studies have compared patients with schizophrenia or schizoaffective disorders to patients with other psychiatric diagnoses without psychosis, addressing ability to quit and differences in treatment characteristics... - Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography studyIsabelle Boileau
Addiction Imaging Research Group, Vivian M Rakoff PET Imaging Centre, Human Brain Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
J Neurosci 32:1353-9. 2012..Pharmacological studies are needed to establish whether normalization of D3 receptor function could reduce vulnerability to relapse in stimulant abuse... 
Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disordersDominique Morisano
Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario
Can J Psychiatry 54:356-67. 2009....- Transcranial magnetic stimulation to understand the pathophysiology and treatment of substance use disordersMera S Barr
Schizophrenia Program, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ontario, Canada
Curr Drug Abuse Rev 1:328-39. 2008..Further work is needed to enhance our understanding of the altered neurophysiology in SUDs as well as the ways in which rTMS treatment can be directed to optimize treatment... - Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disordersIngrid Bacher
University of Toronto, Department of Psychiatry, Faculty of Medicine, Toronto, Canada
Expert Opin Pharmacother 10:2709-21. 2009..These areas of investigation for mecamylamine are reviewed and recommendations for future research directions are proposed... - Treatment of tobacco dependence: integrating recent progress into practiceBernard Le Foll
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ont
CMAJ 177:1373-80. 2007..Specifically, we discuss the use of nicotine replacement therapy, bupropion and varenicline in primary care settings... - Pharmacogenetics of alcohol, nicotine and drug addiction treatmentsJessica E Sturgess
Centre for Addiction and Mental Health, Pharmacogenetics Research Clinic, 250 College Street, Toronto, Ontario, Canada
Addict Biol 16:357-76. 2011.... - Smoking cue reactivity in adult smokers with and without depression: a pilot studyAndrea H Weinberger
Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Am J Addict 21:136-44. 2012..The association between depression symptoms and smoking urges was not significant in the Brief Deprivation Condition. Smoking cue reactivity may be a useful procedure for studying aspects of smoking behavior in adults with depression... - Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophreniaKristi A Sacco
Schizophr Res 103:326-7. 2008 - Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophreniaAndrea H Weinberger
Program for Research on Smokers with Mental Illness PRISM, Yale University School of Medicine, Department of Psychiatry, 34 Park Street, New Haven, CT 06519, USA
Schizophr Res 91:217-25. 2007.... - Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trialBenjamin A Toll
Yale University School of Medicine, Department of Psychiatry, New Haven, CT 06511, USA
Psychol Addict Behav 21:534-44. 2007..These data suggest that gain-framed messages may be more persuasive than loss-framed messages in promoting early success in smoking cessation for participants who are engaged in treatment... - Adverse childhood experiences, smoking and mental illness in adulthood: a preliminary studyKristi A Sacco
Program for Research in Smokers with Mental Illness PRISM, Connecticut Mental Health Center, Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Ann Clin Psychiatry 19:89-97. 2007..This study was designed to examine effects of ACE on the expression of smoking behavior and mental illness in adulthood... - Acute tryptophan depletion in schizophrenic patients treated with clozapineTony P George
Arch Gen Psychiatry 59:291-2. 2002 - A placebo controlled trial of bupropion for smoking cessation in schizophreniaTony P George
Program for Research in Smokers with Mental Illness and Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Biol Psychiatry 52:53-61. 2002.... - Smoking cessation and panic attacks: a report of 2 casesJennifer C Vessicchio
J Clin Psychiatry 63:594-5. 2002 - Current pharmacological treatments for nicotine dependenceTony P George
Center for Nicotine and Tobacco Use Research at Yale, Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, Room S 109, SAC, New Haven, CT 06519, USA
Trends Pharmacol Sci 25:42-8. 2004..Several existing medications are being tested as treatments for nicotine dependence and novel investigational agents are under development as effective treatments for nicotine dependence in the 'hard to treat' tobacco user... - Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophreniaSara L Dolan
Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, 34 Park Street, Rm. S-109, Substance Abuse Center, New Haven, CT 06519, USA
Schizophr Res 70:263-75. 2004..These preliminary data suggest that in schizophrenics, neuropsychological deficits are associated with smoking cessation treatment failure... - Non-nicotine pharmacotherapies for nicotine dependenceMelissa M Dudas
Program for Research in Smokers with Mental Illness (PRISM, Connecticut Mental Health Center, New Haven, CT, USA
Essent Psychopharmacol 6:158-72. 2005..Studies summarizing the effectiveness (or lack thereof) of other (off-label) agents, such as tricyclic antidepressants, MAO-Inhibitors, SSRIs, and clonidine, are cited... - Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanismsKristi A Sacco
Program for Research in Smokers with Mental Illness, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Arch Gen Psychiatry 62:649-59. 2005..These findings may have implications for understanding the high rates of smoking in schizophrenia and for developing pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia... - A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanismsTony P George
Program for Research in Smokers with Mental Illness PRISM, Department of Psychiatry, Yale University School of Medicine, Substance Abuse Center, Connecticut Mental Health Center, New Haven, CT 06519, USA
Schizophr Res 87:307-15. 2006..We evaluated the effects of cigarette smoking on PPI deficits in schizophrenia, and the role of nicotinic acetylcholine receptors (nAChRs) in mediating cigarette smoking-related PPI enhancement... - Reliability of the Fagerström Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophreniaAndrea H Weinberger
Program for Research on Smokers with Mental Illness, Yale University School of Medicine, New Haven, CT 06511, USA
Drug Alcohol Depend 86:278-82. 2007..65 versus 0.79), and TQSU Factor 2 (0.69 versus 0.81), but did not differ between diagnostic groups for M-NWS (0.58 versus 0.64). Our findings suggest that these measures may be reliable for use in smokers with schizophrenia... - Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonistKristi A Sacco
Program for Research in Smokers with Mental Illness PRISM, Yale University School of Medicine, New Haven, CT 06519, USA
Schizophr Res 85:213-21. 2006.... - Treatment of patients with substance use disorders, second edition. American Psychiatric AssociationHerbert D Kleber
Am J Psychiatry 164:5-123. 2007 - The potential of dopamine agonists in drug addictionThomas R Kosten
Yale University School of Medicine, VA Connecticut Healthcare System, Department of Psychiatry, West Haven, CT 06516, USA
Expert Opin Investig Drugs 11:491-9. 2002..Animal studies also suggest that tailoring treatment to subgroups of patients based on genotype may improve responses... - Neurocognitive performance among alcohol dependent men with and without physical violence toward their partners: a preliminary reportCaroline J Easton
Department of Psychiatry, Division of Substance Abuse, Yale University School of Medicine SATU, New Haven, Connecticut 06511, USA
Am J Drug Alcohol Abuse 34:29-37. 2008..The authors examined neurocognitive performance among treatment-seeking alcohol dependent men with (IPV+) and without reported physical violence (IPV-)... - Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary studyTony P George
Division of Substance Abuse, Department of Psychiatry, Program for Research in Smokers with Mental Illness, Yale University School of Medicine, New Haven, CT, USA
J Clin Psychopharmacol 28:340-4. 2008..We compared the nicotinic antagonist, mecamylamine hydrochloride (MEC), with placebo as an augmentation strategy for patients with MDD who were refractory to selective serotonin reuptake inhibitor (SSRI) treatment... - A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessationTony P George
Program for Research in Smokers with Mental Illness (PRISM, New Haven, Connecticut 06519, USA
Biol Psychiatry 53:136-43. 2003..CONCLUSION: This preliminary study suggests that selegiline (10 mg/day) is safe for use and enhances smoking cessation rates compared with placebo in nicotine-dependent cigarette smokers... - Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot studyGerardo Gonzalez
Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA
Addiction 98:1625-32. 2003..We sought to evaluate the safety and efficacy of the GABAergic agent tiagabine in reducing cocaine use among methadone-treated patients... - Survey of clinician attitudes toward smoking cessation for psychiatric and substance abusing clientsAndrea H Weinberger
Program for Research in Smokers with Mental Illness PRISM, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
J Addict Dis 27:55-63. 2008..We suggest that mental health clinicians can be instrumental in providing information, encouragement, and opportunities for their patients to attempt smoking cessation... - Effects of acute tobacco abstinence in adolescent smokers compared with nonsmokersAnne E Smith
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
J Adolesc Health 43:46-54. 2008..This study aimed to prospectively document tobacco abstinence-induced changes during the first 48 hours of abstinence in adolescent smokers compared with nonsmokers, to distinguish effects distinct from typical adolescent lability... - Characteristics of tobacco-smoking problem gamblers calling a gambling helplineMarc N Potenza
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
Am J Addict 13:471-93. 2004..The high proportion of callers reporting daily tobacco smoking highlights the need for enhanced smoking cessation efforts in problem gamblers... - Smoking cue reactivity in schizophrenia: effects of a nicotinic receptor antagonistMargaret A Fonder
Program for Research in Smokers with Mental Illness (PRISM, Connecticut Mental Health Center, and Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Biol Psychiatry 57:802-8. 2005..CONCLUSIONS: Our findings suggest that blockade of CR by MEC may be more robust in schizophrenia versus control smokers, possibly due to reduced nAChR levels in the brains of patients with schizophrenia... - Cigarette smoking in Chinese male inpatients with schizophrenia: a cross-sectional analysisYi lang Tang
Beijing Anding Hospital, Capital University of Medical Sciences, Beijing, China
J Psychiatr Res 41:43-8. 2007..Accordingly, cigarette smoking may be associated with certain clinical features in schizophrenic patients, and should be carefully screened for when making treatment and rehabilitation plans... - Effects of smoking abstinence on visuospatial working memory function in schizophreniaTony P George
Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
Neuropsychopharmacology 26:75-85. 2002..These results suggest that smoking abstinence differentially alters VSWM in schizophrenic vs. control smokers, and that cigarette smoking has beneficial effects on VSWM in schizophrenic, but not control, smokers...